Managing Progressive Non-Small Cell Lung Cancer
Meeting Series
Meeting Series

Managing Progressive Non-Small Cell Lung Cancer

Second-Line Therapy and Beyond

Not a member of My prIME? Join now for instant access.

These CME-certified meetings will discuss the rapidly changing treatment landscape in advanced lung cancer with a focus on second- and later-line treatment options for patients with non-oncogene driven adenocarcinoma and squamous non-small cell lung cancer (NSCLC), including immunotherapy and chemotherapy in combination with antiangiogenic agents. Factors that may impact treatment selection will be evaluated in the context of a clinical case.

CME

CME

1.0 AMA PRA Category 1 Credit™

Palo Alto, California

This educational activity is closed to industry, and is only open to VA Palo Alto Healthcare System healthcare professionals. There is no fee for this activity and preregistration is not required.

Monday, October 1, 2018
5.00 PM – 6.00 PM

VA Palo Alto Healthcare System
3801 Miranda Avenue
Palo Alto, California

Faculty

Millie Das, MD
VA Palo Alto Health Care System
Stanford Cancer Center
Palo Alto, California, United States

New York, New York

This educational activity is closed to industry, and is only open to Lenox Hill Hospital healthcare professionals. There is no fee for this activity and preregistration is not required.

Tuesday, October 23, 2018
8.00 AM – 9.00 AM

Lenox Hill Hospital
130 East 77th Street
New York, New York 10065

Faculty

Benjamin P. Levy, MD
Johns Hopkins Sidney Kimmel Cancer Center
Washington, DC, United States

Washington, DC

This educational activity is closed to industry, and is only open to United Medical Center Hospital healthcare professionals. There is no fee for this activity and preregistration is not required.

Wednesday, November 14, 2018
12.30 PM – 1.30 PM

United Medical Center Hospital
1310 Southern Avenue
Washington, DC 20032

Faculty

Benjamin P. Levy, MD
Johns Hopkins Sidney Kimmel Cancer Center
Washington, DC, United States

Brooklyn, New York

This educational activity is closed to industry, and is only open SUNY Downstate healthcare professionals. There is no fee for this activity and preregistration is not required.

Friday, November 16, 2018
8.00 AM – 9.00 AM

SUNY Downstate
395 Lennox Road
Brooklyn, New York 11203

Faculty

Kristen Marrone, MD
Johns Hopkins Hospital
Baltimore, Maryland, United States

Brooklyn, New York

This educational activity is closed to industry, and is only open Interfaith Medical Center healthcare professionals. There is no fee for this activity and preregistration is not required.

Thursday, November 29, 2018
4.00 PM – 5.00 PM

Interfaith Medical Center
1545 Atlantic Avenue
Brooklyn, New York 11213

Faculty

Rathi Pillai, MD
Winship Cancer Institute
Emory University
Atlanta, Georgia, United States

Salisbury, Maryland

This educational activity is closed to industry, and is only open to Peninsula Regional Medical Center healthcare professionals. There is no fee for this activity and preregistration is not required.

Friday, December 7, 2018
TBD

Peninsula Regional Medical Center
100 East Carroll Street
Salisbury, Maryland 21801

Faculty

Leora Horn, MD
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States

  • Welcome and introduction
  • Treatment algorithm for advanced NSCLC: Focus on choices after progression on first-line therapy in non-driver NSCLC
  • Factors influencing second- and later-line treatment decisions
  • Interactive case-based discussion
  • prIME Points™
  • Adjourn

  • Benjamin P. Levy, MDJohns Hopkins Sidney Kimmel Cancer Center
    Washington, DC, United States
  • Aaron Lisberg, MDUCLA Medicine
    Los Angeles, California, United States
  • Leora Horn, MDVanderbilt-Ingram Cancer Center
    Nashville, Tennessee, United States
  • Rathi Pillai, MDWinship Cancer Institute
    Emory University
    Atlanta, Georgia, United States

This educational meeting series is designed for the healthcare team that treats and manages patients with lung cancer including: Medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, surgeons, nurses, nurse practitioners, physician assistants, and other healthcare professionals.

After successful completion of this educational activity, participants should be able to:

  • Identify patient and disease characteristics to be considered during treatment decision making for patients with progressive NSCLC
  • Assess second- and third-line treatment options for advanced squamous and nonsquamous NSCLC, including immunotherapy and antiangiogenic therapy
  • Select the optimal sequence of therapy for individual patients with advanced NSCLC who progressed on platinum-based therapy and/or immunotherapy

This educational activity is supported by a grant from Lilly.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Managing Progressive Non-Small Cell Lung Cancer

prIME Oncology designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider

This activity is provided by prIME Oncology.

Sunshine Act/EFPIA

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.

Disclosures

Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.